Physician engagement platform KeyOps closes C$4m seed round

KeyOps has developed a digital platform that connects doctors and other opinion leaders to life science companies to enable faster commercial decision-making and a better response to patients' needs.

  • The round was led by Graphite Ventures, with participation from MaRS Investment Accelerator Fund, StarForge, an Archangel Network fund and Velocity Fund
  • Several software-as-a-service executives also invested
  • KeyOps will use the funds raised to fuel expansion in the US while growing its physician network across North America

KeyOps, a Toronto-based physician engagement platform, has secured C$4 million in seed financing.

The round was led by Graphite Ventures, with participation from MaRS Investment Accelerator Fund, StarForge, an Archangel Network fund and Velocity Fund. Several software-as-a-service executives also invested, among them Carol Leaman, CEO of Axonify, James Novak, ex-CEO of Fiix Software, and Danny Ardellini, CEO of Environmental 360 Solutions, as well as a network of physicians from HaloHealth.

KeyOps has developed a digital platform that connects doctors and other opinion leaders to life science companies to enable faster commercial decision-making and a better response to patients’ needs. Since rolling out the platform in 2021, it has signed prominent pharmaceutical and medical device customers, including Amgen, GlaxoSmithKline, Sanofi Canada and Becton, Dickinson and Company.

KeyOps will used the funds raised will be used to grow the team, with a focus on engineering, product development and sales/marketing roles, to expand its US market reach. The company will also increase its North American physician network.

“There are a number of small players who are attempting to enable commercial insights for life science sales and marketing teams,” said Graphite venture partner and new KeyOps board director Kevin Madill in a statement. “KeyOps is the first to take an innovative physician-centric approach and we were impressed with their vision for building a collaborative and modern approach to physician-pharma engagement.”

Based in Toronto, Graphite is an early-stage seeding-for-scale venture capital firm that invests in early-stage B2B SaaS, fintech, proptech, digital health and capital-efficient hardware companies. The firm launched the $100 million Graphite Fund IV in 2021.